Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer

Journal of Clinical Oncology

Volumn 25, Issue 4, 2007, Pages 384-389

  Axtell, Allison E ^a   Lee, Margaret H ^a   Bristow, Robert E ^a   Dowdy, Sean C ^a   Cliby, William A ^a   Raman, Steven ^a   Weaver, John P ^a   Gabbay, Mojan ^a   Ngo, Michael ^a   Lentz, Scott ^a   Cass, Ilana ^a   Li, Andrew J ^a   Karlan, Beth Y ^a   Holschneider, Christine H ^a  

^a OLIVE VIEW UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIVARIATE ANALYSIS; OVARY CANCER; PREDICTOR VARIABLE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RADIOLOGIST; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; VALIDATION STUDY; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; OVARY TUMOR; PATHOLOGY; PREDICTION AND FORECASTING; RADIOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 33846995117     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.7800     Document Type: Article

References (31)

1. American Cancer Society. Cancer Facts & Figures 2005. http://www.cancer.org/downloads/STT/CAFF2005f4PWSecured.pdf
2. Bristow RE, Tomacruz RS, Armstrong DK, et al: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 20:1248-1259, 2002
3. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
4. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 27:3194-3200, 2003
5. Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43, 2006
6. Holschneider CH, Berek JS: Cytoreductive surgery: Principles and rationale, in Bristow RE, Karlan BY, Montz FJ (eds): Surgery for Ovarian Cancer: Principles and Practice. Lancaster, United Kingdom, The Parthenon Publishing Group, 2005, pp 141-143
7. Hoskins WJ, McGuire WP, Brady MF, et al: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170:974-979, 1994
8. Schwartz PE, Rutherford TJ, Chambers JT, et al: Neoadjuvant chemotherapy for advanced ovarian cancer: Long term survival. Gynecol Oncol 72:93-99, 1999
9. Kayikciog F, Rose MF, Boran N, et al: Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian cancer. Int J Gynecol Cancer 11:466-470, 2001
10. Fanfani F, Ferrandina G, Corrado G, et al: Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIC ovarian cancer patients. Oncology 65:316-322, 2003
11. Morice P, Dubernard G, Rey A, et al: Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coll Surg 197:955-963, 2003
12. Shibata K, Kikkawa F, Mika M, et al: Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: Survival benefit and prognostic factors. Int J Gynecol Cancer 13:587-592, 2003
13. Ansquer Y, LeBlanc E, Clough K, et al: Neoadjuvant chemotherapy for nonresectable ovarian carcinoma: A French multicenter study. Cancer 91: 2329-2334, 2001
14. Kuhn W, Rutke S, Spathe K, et al: Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics stage IIIC ovarian carcinoma. Cancer 92:2585-2591, 2001
15. Vergote I, DeWever I, Tjalma W, et al: Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: A retrospective analysis of 285 patients. Gynecol Oncol 71:431-436, 1998
16. European Organization for Research and Treatment of Cancer: Randomized phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy in patients with stage IIIc or IV epithelial ovarian cancer (EORTC protocol 55971). http://www.eortc.be/protoc/Details.asp?Protocol=55971
17. Chi DS, Venkatraman ES, Masson V, et al: The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 77:227-231, 2000
18. Gemer O, Segal S, Kopmar A, et al: Preoperative CA-125 level as a predictor of non-optimal cytoreduction of advanced epithelial ovarian cancer. Acta Obstet Gynecol Scand 80:583-585, 2001
19. Saygili U, Guclu S, Uslu T, et al: Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma? Gynecol Oncol 86:57-61, 2002
20. Cooper BC, Sood AK, Davis CS, et al: Preoperative CA-125 levels: An independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol 100:59-64, 2002
21. Memarzadeh S, Lee SB, Berek JS, et al: CA-125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 13:120-124, 2003
22. Dowdy SC, Mullany SA, Brandt KR, et al: The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer 101:346-352, 2004
23. Brockbank EL, Ind TE, Barton DP, et al: Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer. Int J Gynecol Cancer 14:42-50, 2004
24. Nelson BE, Rosenfield AT, Schwartz PE: Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 11:166-172, 1993
25. Meyer JI, Kennedy AW, Friedman R, et al: Ovarian carcinoma: Value of CT in predicting success of debulking surgery. Am J Roentgenol 165: 875-878, 1995
26. Bristow RE, Duska LR, Lambrou NC, et al: A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 89:1532-1540, 2000
27. Qayyum A, Coakley FV, Westphalan AC, et al: Role of CT and MRI imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol 96:301-306, 2005
28. Alberts DS, Liu PY, Hannigan EV, et al: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950-1955, 1996
29. Markman M, Bundy BN, Alberts DS, et al: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001-1007, 2001
30. Bristow RE, Chi DS: Platinum-based neoadjuvant chemotherapy and interval cytoreduction for advanced ovarian cancer: A meta-analysis. Gynecol Oncol 103:1070-1076, 2006
31. Aletti GD, Gostout BS, Podratz KC, et al: Ovarian cancer surgical resectability: Relative impact of disease, patient status, and surgeon. Gynecol Oncol 100:33-37, 2006